The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.
April 19th 2024
In case you missed any, below is a recap of every episode of OncLive On Air that aired in March 2024.
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Medical Crossfire®: Critical Questions on Diagnosis, Sequencing, and Selection of Systemic and Radioligand Therapy Options for Patients with GEP-NETs
View More
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Advances In™: Targeting PSMA to Advance Diagnosis And Management Of Patients With Prostate Cancer
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
2023 ASCO Direct™ Highlights: Practice-Changing Data From the Leading Oncology Conference
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…
View More
Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Dr Sieber on the Importance of Evaluating Comorbidities in Prostate Cancer Prior to ADT
August 3rd 2023Paul Sieber, MD, discusses the importance of evaluating comorbidities in patients with prostate cancer, including assessing risk factors for cardiovascular events in those who are initiating androgen deprivation therapy.
Analysis Helps Distinguish the Molecular Profile of Intraductal Carcinoma of the Prostate
July 31st 2023Benjamin Miron, MD, explains the purpose of studying the molecular profile of intraductal carcinoma of the prostate, expands on the potential prognostic and targetable alterations identified in patients with this histology, and discusses the planned cohort expansion and analysis of RNA signatures in this population.
Dr Agarwal on Future Questions to Address Following the TALAPRO-2 Trial in mCRPC
July 26th 2023Neeraj Agarwal, MD, discusses future questions to be addressed following the phase 3 TALAPRO-2 trial evaluating the combination of talazoparib plus enzalutamide in patients with metastatic castration-resistant prostate cancer.
Varied levels of compliance were observed in terms of using validated quality indicators to determine the quality of active surveillance for patients with low-risk prostate cancer, according to findings from a population-based study published in the Journal of the Comprehensive Cancer Network.
NCCN Adds Flotufolastat F 18 Injection to Clinical Practice Guidelines for Prostate Cancer
The National Comprehensive Cancer Network has added flotufolastat F 18 injection to its Clinical Practice Guidelines in Oncology for positron emission tomography of prostate-specific membrane antigen–positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy.
FDA Awards Fast Track Designation to ARX517 for Metastatic Castration-Resistant Prostate Cancer
The FDA has granted fast track designation to ARX517 for use as a potential treatment option in patients with metastatic castration-resistant prostate cancer who experience disease progression on an androgen receptor pathway inhibitor.
Agarwal Discusses FDA Approval of Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC
Neeraj Agarwal, MD, speaks on the significance of the approval and how the combination of talazoparib and enzalutamide will fit into the treatment landscape of HRR gene–mutated mCRPC.
Dr Lowentritt on the Rationale for Investigating Real-World PSA Response to AR Inhibitors in mCSPC
July 18th 2023Benjamin H. Lowentritt, MD, FACS, discusses the background and rationale for conducting a real-world retrospective study of prostate-specific antigen responses generated from second-generation androgen receptor inhibitors in patients with metastatic castration-sensitive prostate cancer.
Dr Lowentritt on the Implications of Data on Real-World ASRI Efficacy in mCSPC
July 13th 2023Benjamin H. Lowentritt, MD, FACS, discusses how results from a real-world retrospective study of responses with second-generation androgen receptor signaling inhibitors in patients with mCSPC could affect the selection and use of next-generation ARSIs in practice, and how this research identifies several other unanswered questions for future investigation.
Dr Agarwal on Advances With PARP Inhibitors in Prostate Cancer
July 10th 2023Neeraj Agarwal, MD, discusses the role of PARP inhibitors in metastatic castration-resistant prostate cancer and the potential evolutions of the metastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer treatment paradigms.
Lutetium Lu 177 Vipivotide Tetraxetan Provides HRQOL Benefit, Reduces Skeletal Events in mCRPC
The addition of lutetium Lu 177 vipivotide tetraxetan to standard-of-care treatment delayed time to worsening of health-related quality of life and skeletal events compared with standard of care alone for patients with metastatic castration-resistant prostate cancer.
Dr Agarwal on the FDA Approval of Talazoparib Plus Enzalutamide in HRR-Mutated mCRPC
July 6th 2023Neeraj Agarwal, MD, discusses the significance of the FDA approval of talazoparib plus enzalutamide in patients with metastatic castration-resistant prostate cancer harboring homologous recombination repair gene alterations.
PSCA-Targeted CAR T-Cell Therapy Demonstrates Safety, Anticancer Activity in mCRPC
The use of prostate stem cell antigen–targeted CAR T-cell therapy was well tolerated and produced evidence of anticancer effects in patients with metastatic castration-resistant prostate cancer.
Systemic Treatment Armamentarium in Metastatic HSPC
Shared insight on the range of systemic therapy options available to patients who present with metastatic hormone-sensitive prostate cancer.